OVID Surges 16% on Capital Raise — But Volume Tells a Different Story

Ovid Therapeutics (NASDAQ: OVID) stock news has dominated pre-market sessions as the small-cap biotech surged nearly 16% to $2.33 on March 18. The sharp move followed a major capital raise and hints of progress in its key drug candidate, OV329. With the Nasdaq Composite futures up 0.59% and broader market momentum leaning bullish, investors are asking: Is OVID’s rally sustainable, or is it a short-lived pop?

The immediate trigger for the surge was a private placement announcement—Ovid secured $60 million in fresh capital to advance OV329 for two rare seizure disorders. That said, the stock’s performance is also being framed within the context of its technical setup. Over the past 60 days, the stock has traded between $1.26 and $2.37, with today’s price near the upper end of that range. Crucially, the 7 mg dose of OV329 has shown positive early safety data, adding a speculative layer to the capital news.

Why is OVID stock dropping today?

Ovid’s price move isn’t a drop—it’s a surge. That said, the question of why the stock isn’t seeing more robust volume support remains. Despite a 15.9% gain in pre-market trading, the volume today has only been 432,781 shares, far below its average 20-day volume of 1.73 million. This weak confirmation suggests the move is more speculative or news-driven than backed by broad institutional buying.

Still, the price has already crossed above both its 20-day and 50-day moving averages, which currently sit at $1.74 and $1.67, respectively. The RSI is at 74.4, bordering overbought territory, and the stock is trading in the 96th percentile of its 60-day range. This suggests that the rally is fast and sharp, but not yet deeply entrenched.

What to watch for technical levels and next steps?

For now, the key price levels to watch are $2.37 (resistance) and $2.01 (support). If the stock holds above $2.01, it could continue to test the $2.37 level, which represents the high of the past 60 days. A breakout above that threshold with stronger volume would signal a potential shift into a more defined uptrend. On the flip side, a pullback below $2.01 could reignite concerns about the stock’s sustainability. The 50-day moving average at $1.67 serves as a deeper support. A breakdown there would likely validate a more bearish scenario, especially if the volume increases on the way down. In practice, this makes $2.01 a critical pivot point for near-term direction.

OVID support and resistance levels

The nearest resistance at $2.37 sits just 1.7% above the current price, while the nearest support at $2.01 is 13.7% lower. The stock’s current position in the upper range suggests traders are either betting on a breakout or hedging against a possible pullback.

The ATR (Average True Range) over 14 days is $0.166, indicating that the stock is volatile but not yet in a breakout phase. A move above $2.37 would need to hold for multiple sessions to be considered a valid breakout. For now, the stock remains in a continuation pattern within the range. The bottom line? Ovid is in a tight trading window, and the coming sessions will tell whether today’s pop is the start of a trend or a false flag.

What to watch in the next few days? A strong follow-through on volume and price action above $2.37, or a test of $2.01 to see whether bulls can defend the key support. For now, Ovid’s rally is real but fragile. Investors should remain cautious and watch for confirmation—or the lack of it—before committing to a long-term position.